Potential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair says

The dream to see arimoclomol approved as a Niemann-Pick type C treatment will not die with Orphazyme, should the firm be dissolved through a takeover, Deputy Chair Bo Jesper Hansen tells MedWatch.
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

Embattled biotech firm Orphazyme announced last week that several potential buyers had made bids to buy all of the company’s assets and operations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading